Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

Today, ARCH Biopartners Inc., ("ARCH" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that it has safely increased the maximum daily dose of LSALT peptide to 20 mg per day in healthy, normal volunteers in a recently completed human trial in Australia.

LSALT peptide is the Company's lead drug candidate for treating inflammation in the lungs, liver and kidneys and Arch intends to use the new maximum dose in designing a Phase II trial targeting cardiac surgery-associated acute kidney injury (CS-AKI). The new safety data will be included in an Investigational New Drug Application to the U.S. FDA, to be submitted in relation to the CS-AKI trial in due course.

Prior to this dose escalation trial, LSALT peptide was administered at a maximum of 5mg once daily, for up to 14 days, in hospitalized COVID-19 patients during a Phase II trial targeting inflammation in the lungs.

Dose Escalation Trial

The dose escalation human trial was performed at the Alfred Hospital in Melbourne, Australia. The trial was a double-blind, placebo-controlled, randomized, single and multiple ascending dose study to evaluate the safety and pharmacokinetic profile of LSALT peptide. Sixteen healthy, normal volunteers participated, receiving either LSALT peptide or a placebo, and were divided into two groups.

Six participants in each group received a daily dosing of LSALT peptide for one day followed by three consecutive days of dosing. Two people per group received a placebo with the same dosing schedule. In the first group, six people received a once daily, 10 mg intravenous (IV) dose of LSALT peptide. In the second group, six volunteers received a 10 mg IV dose of LSALT peptide twice a day, approximately every 12 hours.

In both groups, LSALT peptide met the primary endpoints of safety and tolerability.

LSALT Peptide Drug Product Manufacturing Update

During the last few months, Arch has continued to advance the production of new supply of LSALT peptide to be used in non-Covid human trials. The production of approximately 10,000 LSALT peptide drug product vials has recently been completed. The new vials are undergoing quality control and quality assurance procedures at the Company's third-party manufacturing facility in Toronto, Canada. The drug product vials contain approximately 5mg of LSALT peptide and are expected to be released to Arch in May 2023.

About Arch Biopartners

Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch Biopartners is developing a pipeline of new drug candidates that inhibit inflammation in the lungs, kidneys and liver via the dipeptidase-1 (DPEP-1) pathway, relevant for multiple medical indications.

For more information on Arch Biopartner's science and technologies, please visit: www.archbiopartners.com/our-science

For investor information and other public documents the company has also filed on SEDAR, please visit www.archbiopartners.com/investor-hub

The Company has 62,398,825 common shares outstanding.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of our future performance, liquidity and capital resources, as well as the ongoing clinical development of our drug candidates targeting the dipeptidase-1 (DPEP-1) pathway, including the outcome of our clinical trials relating to LSALT Peptide (Metablok), the successful commercialization and marketing of our drug candidates, whether we will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe and other countries, our ability to raise capital to fund our business plans, the efficacy of our drug candidates compared to the drug candidates developed by our competitors, our ability to retain and attract key management personnel, and the breadth of, and our ability to protect, our intellectual property portfolio. These statements are based on management's current expectations and beliefs, including certain factors and assumptions, as described in our most recent annual audited financial statements and related management discussion and analysis under the heading "Business Risks and Uncertainties". As a result of these risks and uncertainties, or other unknown risks and uncertainties, our actual results may differ materially from those contained in any forward-looking statements. The words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We undertake no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including our most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval ("SEDAR") website at www.sedar.com .

The science and medical contents of this release have been approved by the Company's Chief Science Officer.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release .


For more information, please contact: Richard Muruve Chief Executive Officer Arch Biopartners, Inc. 647-428-7031 info@archbiopartners.com 

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ARCH
The Conversation (0)
First Helium Licenses Second of Two Wells Targeting Leduc Light Oil at Worsley

First Helium Licenses Second of Two Wells Targeting Leduc Light Oil at Worsley

First Helium Inc. ("First Helium" or the "Company") (TSXV: HELI) (OTCQB: FHELF) (FRA: 2MC) today announced receipt of regulatory licensing approval to proceed with the drilling of its 7-15 high impact exploration location, along with its previously licensed proven undeveloped ("PUD") 7-30 location, which has been assigned proved plus probable undeveloped reserves of 196,700 barrels² by Sproule Associates Limited ("Sproule")¹, its independent evaluator. The Company is working to secure drilling and ancillary services to drill both wells in a sequential, cost-effective manner. In preparation, the Company has commenced construction of the 7-30 drilling location.

"With drilling license now in hand for the 7-15 location, we are moving ahead to secure the required services necessary to drill both our 7-30 PUD well along with our high impact Leduc anomaly, 7-15, which on seismic is approximately 5X the areal extent of our successful 1-30 light oil pool discovery," said Ed Bereznicki, President & CEO of First Helium. "With success, the combined oil potential from these two operations would provide immediate cash flow and meaningful near-term value for our shareholders. It would also set the stage to execute on ten additional, highly prospective lower risk drilling locations," added Mr. Bereznicki.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
First Helium Licenses First of Two Wells Targeting Leduc Light Oil at Worsley

First Helium Licenses First of Two Wells Targeting Leduc Light Oil at Worsley

First Helium Inc. ("First Helium" or the "Company") (TSXV: HELI) (OTCQB: FHELF) (FRA: 2MC) today announced receipt of regulatory licensing approval to proceed with the drilling of its proven undeveloped ("PUD") 7-30 location, which has been assigned proved plus probable undeveloped reserves of 196,700 barrels 2 by Sproule Associates Limited ("Sproule") 1 its independent evaluator. The Company continues to advance the licensing process for its high-impact 7-15 Leduc anomaly target and is working to secure drilling and ancillary services to drill both wells in a sequential, cost-effective manner.

"With drilling license in hand for the 7-30 PUD location, we are moving ahead to secure the required services necessary to drill both our 7-30 PUD well along with our high impact Leduc anomaly, 7-15, which on seismic is approximately 5X the areal extent of our successful 1-30 light oil pool discovery," said Ed Bereznicki, President & CEO of First Helium. "With success, the combined oil potential from these two operations would provide immediate cash flow and meaningful near-term value for our shareholders. It would also set the stage to execute on ten additional, highly prospective lower risk drilling locations," added Mr. Bereznicki.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
First Helium Reviewing Potential Follow Up Targets to Leduc Anomaly Drill

First Helium Reviewing Potential Follow Up Targets to Leduc Anomaly Drill

First Helium Inc. ("First Helium" or the "Company") (TSXV: HELI) (OTCQB: FHELF) (FRA: 2MC) today announced that it is reviewing its extensive drilling inventory for follow up operations to its planned Leduc anomaly drill ("7-15") targeting light oil. This program may include drilling its proven undeveloped 1, 3 location ("7-30"), a follow up well on the Leduc anomaly, or another one of 12 primary Leduc prospects identified on its proprietary 3D seismic at Worsley. Other operations include completion and testing of the existing 5-27 horizontal well, along with the re-entry and completion of an existing vertical well bore at east Worsley, both targeting helium-enriched natural gas in the Blue Ridge formation to establish a regional, repeatable play.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
First Helium Closes Upsized $3.64 Million Placement

First Helium Closes Upsized $3.64 Million Placement

Not for distribution to United States newswire services or for dissemination in the United States.

First Helium Inc. ("First Helium" or the "Company") (TSXV: HELI) (OTCQB: FHELF) (FRA: 2MC) today announced the closing of its upsized non-brokered private placement financing which was previously announced in the Company's press release dated October 16, 2024 and October 21, 2024. First Helium issued 60,666,671 units ("Units") at a price of $0.06 per Unit for gross proceeds of $3,640,000.26 (the "Offering) . All monetary figures in Canadian Dollars.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
GTI Energy

Lo Herma ISR Uranium Project, Resource Drilling Funded

Following the recently completed placement to sophisticated and institutional shareholders, GTI Energy Ltd (GTI or Company) is pleased to provide an update on the upcoming resource expansion drilling program at the Lo Herma ISR uranium project in Wyoming’s Powder River Basin (PRB). In advance of further news related to progress of the planned drill program at Lo Herma, the following provides a summary of the resource expansion potential and objectives of the 2024 Phase II drilling.

Keep reading...Show less
Asian Battery Metals PLC

High grade Massive Sulphide Intercepts Confirmed at Oval

Asian Battery Metals PLC (ABM or the Company, ASX: AZ9) is pleased to announce the remaining laboratory assay results of the 2024 Phase 2 drilling program for samples from drillholes OVD026, OVD027, OVD028, and OVD029. The details of the assays are provided in Table 1.
Keep reading...Show less
Stock chart over globe.

Canadian Markets Steady Amid Trump Tariff Speculation and Renewed Greenland Interest

Canada's main stock index gained on Wednesday (January 8), driven by strength in tech and mining stocks.

Investors continue to weigh the impact of potential US trade policy changes under President-elect Donald Trump, as well as his renewed interest in taking ownership of Greenland, an idea he first raised in 2019.

The S&P/TSX Composite Index (INDEXTSI:OSPTX) closed at 25,049.66, recovering from two consecutive sessions of losses following Justin Trudeau's resignation as Canadian prime minister on Monday (January 6).

Keep reading...Show less
Stock chart with Canadian flag.

Trudeau Resigns, Canadian and US Markets React

Canadian markets showed mixed reactions following Prime Minister Justin Trudeau’s resignation.

The S&P/TSX Composite Index (INDEXTSI:OSPTX) closed lower on Monday (January 6), while the Canadian dollar gained strength against the US dollar, reflecting diverging investor sentiment.

The index dropped by 142.14 points to settle at 24,995.93, marking a 0.57 percent decline from its starting point for the day. Meanwhile, the Canadian dollar rose to 69.7 cents US, reaching a near three week high.

Keep reading...Show less
Australian dollars Australian flag in the background.

5 Australian Mining Grants Open for Applications in 2025

As 2025 begins, companies in the mining sector are gearing up for another year of work.

In Australia, there are many chances for explorers and developers to access government funding at both the state and federal level. The list below includes five programs that are open for applications, or will be soon.

Read on to learn more about what companies can apply and how much money is up for grabs.

Keep reading...Show less
Jay Martin, city skyline and gold bars.

VRIC 2025 Preview — Jay Martin Talks Resource Wars, Geopolitics and How to Invest

The next Vancouver Resource Investment Conference (VRIC) is set to run from January 19 to 20, 2025, and Jay Martin, president of Cambridge House, joined the Investing News Network ahead of time to discuss the event.

Looking at the resource sector, Martin, who also hosts the Jay Martin Show on YouTube, said the current decade has been defined by chaos and uncertainty, with no signs of a slowdown any time soon.

With that in mind, his macro thesis on commodities remains steadfast, and he's watching three key drivers.

Keep reading...Show less
Check mark on wooden blocks.

Queensland to Streamline Mining Approvals Under New Resources Cabinet Committee

Queensland's new Resources Cabinet Committee (RCC) has met for the first time, the government said last week.

The RCC is part of the Crisafulli government’s 100 Day Plan, announced last October. The plan outlines more than 40 actions the government will take in its first 100 days in office, focusing on youth crime, health, housing and cost of living.

“We’ve pulled together the key players in our ministerial team that have a direct impact on resources,” said Minister for Natural Resources and Mines Dale Last, who has been appointed chair of the RCC.

Keep reading...Show less

Latest Press Releases

Related News

×